Literature DB >> 9454802

Protein kinase C inhibitors block amphetamine-mediated dopamine release in rat striatal slices.

L Kantor1, M E Gnegy.   

Abstract

The stimulant drug amphetamine is postulated to enhance dopamine release through the plasmalemmal dopamine transporter by an exchange diffusion with synaptosomal dopamine. Because protein kinase C has been shown to have an effect on dopamine transporter activity, we examined the effect of protein kinase C inhibitors on endogenous dopamine release stimulated by amphetamine in perfused rat striatal slices. At concentrations of 1 microM, the selective protein kinase C inhibitors chelerythrine, Ro31-8220 and calphostin C nearly completely inhibited endogenous dopamine release elicited by 1 microM amphetamine. The inactive analog bisindoylmaleimide V had no effect. Extracellular Ca++ was not required for the effect of the inhibitors. The importance of vesicular dopamine release was examined by determining inhibitor activity in reserpine-treated rats. Dopamine release elicited by 1 microM amphetamine was not significantly altered in reserpine-treated rats compared with control animals. Ro31-8220 at 1 microM completely blocked amphetamine-induced dopamine release in reserpine-treated rats. Activation of protein kinase C with 250 nM of the phorbol ester 12-O-tetradecanoylphorbol 13-acetate increased dopamine release, and the release was not additive with 1 microM amphetamine. Both chelerythrine and Ro31-8220 at 1 microM increased [3H]dopamine uptake by 17% and 30%, respectively, whereas a brief exposure to 12-O-tetradecanoylphorbol 13-acetate slightly inhibited [3H]dopamine uptake. Our results suggest that amphetamine-mediated dopamine release through the plasmalemmal transporter is highly dependent on protein kinase C activity.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9454802

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  59 in total

Review 1.  Protein kinase C isozymes and addiction.

Authors:  M Foster Olive; Robert O Messing
Journal:  Mol Neurobiol       Date:  2004-04       Impact factor: 5.590

2.  Dysregulation of dopamine transporters via dopamine D2 autoreceptors triggers anomalous dopamine efflux associated with attention-deficit hyperactivity disorder.

Authors:  Erica Bowton; Christine Saunders; Kevin Erreger; Dhananjay Sakrikar; Heinrich J Matthies; Namita Sen; Tammy Jessen; Roger J Colbran; Marc G Caron; Jonathan A Javitch; Randy D Blakely; Aurelio Galli
Journal:  J Neurosci       Date:  2010-04-28       Impact factor: 6.167

3.  PKCbeta co-localizes with the dopamine transporter in mesencephalic neurons.

Authors:  Heather A O'Malley; Yanghae Park; Lori L Isom; Margaret E Gnegy
Journal:  Neurosci Lett       Date:  2010-08-09       Impact factor: 3.046

4.  Molecular mechanisms, biological actions, and neuropharmacology of the growth-associated protein GAP-43.

Authors:  John B Denny
Journal:  Curr Neuropharmacol       Date:  2006-10       Impact factor: 7.363

Review 5.  Protein kinases and addiction.

Authors:  Anna M Lee; Robert O Messing
Journal:  Ann N Y Acad Sci       Date:  2008-10       Impact factor: 5.691

6.  Reassessment of models of facilitated transport and cotransport.

Authors:  Richard J Naftalin
Journal:  J Membr Biol       Date:  2010-03-05       Impact factor: 1.843

7.  Ca2+ dependent surface trafficking of norepinephrine transporters depends on threonine 30 and Ca2+ calmodulin kinases.

Authors:  Uhna Sung; Francesca Binda; Valentina Savchenko; William A Owens; Lynette C Daws
Journal:  J Chem Neuroanat       Date:  2016-12-23       Impact factor: 3.052

8.  Differential targeting of the dopamine transporter to recycling or degradative pathways during amphetamine- or PKC-regulated endocytosis in dopamine neurons.

Authors:  Weimin C Hong; Susan G Amara
Journal:  FASEB J       Date:  2013-04-23       Impact factor: 5.191

9.  β-Arrestin-Dependent Dopaminergic Regulation of Calcium Channel Activity in the Axon Initial Segment.

Authors:  Sungchil Yang; Roy Ben-Shalom; Misol Ahn; Alayna T Liptak; Richard M van Rijn; Jennifer L Whistler; Kevin J Bender
Journal:  Cell Rep       Date:  2016-07-21       Impact factor: 9.423

10.  Amphetamine and methamphetamine differentially affect dopamine transporters in vitro and in vivo.

Authors:  J Shawn Goodwin; Gaynor A Larson; Jarod Swant; Namita Sen; Jonathan A Javitch; Nancy R Zahniser; Louis J De Felice; Habibeh Khoshbouei
Journal:  J Biol Chem       Date:  2008-12-01       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.